Ospemifene
Ospemifene (Osphena) is the only oral, non-estrogen FDA-approved treatment for moderate-to-severe dyspareunia and vaginal dryness due to menopause. As a third-generation selective estrogen receptor modulator (SERM), it exerts tissue-specific effects — agonist on vaginal and bone tissue, antagonist on breast tissue, and weak agonist on endometrium — making it a unique option for GSM patients who cannot or prefer not to use vaginal preparations.[1][2][3] Small observational studies have explored bladder symptoms in women with VVA, but OAB and UUI are not approved indications or established treatment roles.[4][5][6]
For related classes, see Vaginal and topical estrogen, Vaginal DHEA, Preoperative hormonal priming, and the clinical GSM article.
Mechanism and tissue-selective SERM profile
Ospemifene is a triphenylethylene derivative (structurally related to tamoxifen and toremifene) with tissue-selective ER modulation:[3]
| Tissue | ER effect | Clinical implication |
|---|---|---|
| Vaginal epithelium | Agonist | Epithelial maturation, ↑ superficial cells, ↓ pH, lubrication[3] |
| Bone | Agonist | ↓ bone-turnover markers; bone-biomarker profile comparable to raloxifene[7][8] |
| Breast | Antagonist | Preclinical anti-proliferative on breast tissue[9] |
| Endometrium | Weak agonist | Endometrial thickening; one simple hyperplasia without atypia and no endometrial cancer in trials up to 52 weeks[10] |
| Cardiovascular / lipids | Mixed | ↑ HDL, ↓ LDL; neutral on triglycerides[11] |
Pharmacokinetics[12]
- Absorption — must be taken with food — a high-fat meal increases Cmax and AUC 2.3× and 1.7× vs fasting
- Protein binding >99% (clinically relevant for drug interactions)
- Volume of distribution 448 L
- Metabolism — primarily CYP3A4 and CYP2C9 (CYP2C19 minor); major metabolite 4-hydroxyospemifene
- Half-life ~26 hours; steady state achieved in ~1 week
- Elimination ~75% fecal, ~7% urinary
FDA-approved indications and dosing
| Element | Details |
|---|---|
| Brand | Osphena[12] |
| FDA indications | (1) Moderate-to-severe dyspareunia of menopause; (2) moderate-to-severe vaginal dryness of menopause (added 2019) |
| Dose | 60 mg PO once daily with food |
| Generic | None as of 2026 |
Contraindications and boxed warning
FDA boxed warning[12]
- Endometrial cancer — estrogen-agonist effect on the endometrium; increased risk of endometrial cancer with unopposed estrogens; evaluate any undiagnosed persistent or recurring abnormal genital bleeding
- Cardiovascular disorders — stroke and DVT risk warnings extrapolated from WHI estrogen-alone data. In ospemifene trials (up to 15 months):
- Thromboembolic stroke: 1.13 per 1,000 woman-years (vs 3.15 placebo)
- Hemorrhagic stroke: 3.39 per 1,000 woman-years (vs 0 placebo)
- DVT: 2.26 per 1,000 woman-years (2 cases) vs 3.15 per 1,000 woman-years (1 case) placebo
Contraindications[12]
- Undiagnosed abnormal genital bleeding
- Estrogen-dependent neoplasia
- Active DVT / PE or history of these
- Active arterial thromboembolic disease (stroke, MI) or history
- Hypersensitivity to ospemifene
- Known or suspected pregnancy
Drug interactions
| Interacting drug | Mechanism | Effect | Clinical action |
|---|---|---|---|
| Fluconazole | Moderate CYP3A / strong CYP2C9 / moderate CYP2C19 inhibitor | ↑ AUC 2.7×, ↑ Cmax 1.7× | Do not co-administer[12] |
| Rifampin | Strong CYP3A / moderate CYP2C9-2C19 inducer | ↓ AUC 58%, ↓ Cmax 51% | Do not co-administer (loss of clinical effect)[12] |
| Ketoconazole | Strong CYP3A inhibitor | ↑ AUC 1.4×, ↑ Cmax 1.5× | Use with caution |
| Omeprazole | Moderate CYP2C19 inhibitor | ↑ AUC 1.17×, ↑ Cmax 1.20× | No dose adjustment needed |
| Warfarin | Protein-binding displacement (ospemifene >99% bound) | No effect on single-dose warfarin PK; chronic INR/PT not studied | Monitor if co-administered |
| Estrogens / other SERMs | Pharmacodynamic | Safety not studied | Do not co-administer |
| Highly protein-bound drugs | Displacement | May alter exposure of either drug | Use with caution |
The fluconazole interaction is particularly relevant in urogynecologic practice — fluconazole is commonly prescribed for VVC in the same patient population.[2]
Pivotal efficacy data
Approval rested on three 12-week efficacy trials + one 52-week safety trial, total 2,516 postmenopausal women (1,416 ospemifene / 1,100 placebo).[12] All four coprimary endpoints met (superficial cells, parabasal cells, vaginal pH, most bothersome symptom).
Di Donato 2019 meta-analysis (6 RCTs)[13]
Ospemifene 60 mg vs placebo at 12 weeks:
- Vaginal pH: SMD −0.96 (95% CI −1.12 to −0.81; p < 0.001)
- Parabasal cells: SMD −1.97 (p < 0.001)
- Superficial cells: SMD +1.74 (p < 0.001)
- Dyspareunia: SMD −0.51 (p < 0.001)
- Dryness: SMD −0.52 (p < 0.001)
Simon 2023 network meta-analysis[14]
The network meta-analysis summarized mean endometrial thickness; this does not mean every patient remained below a diagnostic threshold. The FDA label reports endometrial thickening ≥5 mm and one simple hyperplasia without atypia, with no endometrial cancer during trials through 52 weeks.[12]
Urogynecologic applications beyond dyspareunia
Overactive bladder and urge urinary incontinence — exploratory evidence
| Study | n | Design | Finding |
|---|---|---|---|
| Schiavi 2017 | 46 | Retrospective 12 wk | Detrusor overactivity 39% → 13% (p = 0.04); voids/day 9.57 → 6.63; urgency episodes 5.63 → 1.44; nocturia 3.17 → 1.11; UUI 0.85 → 0.33 (all p ≤ 0.003)[4] |
| Schiavi 2018 | 105 | Prospective 12 wk | OAB-Q 55.34 → 23.22 (p < 0.0001); FSFI significantly improved; PGI-I 90.5% total success rate[5] |
| Novara 2020 | 25 | Prospective 12 wk (first-line-refractory OAB) | Significant reduction in micturition, nocturia, urgency, incontinence; bladder-wall thickness decreased; UDI-6 and OAB-Q improved[6] |
| Russo 2023 | 40 | Prospective 12 wk with urodynamics | Cystometric capacity, compliance, and verbal sensory threshold improved; daily voids, UUI, and nocturia decreased; ICIQ-UI SF and ICIQ-OAB improved[15] |
The 25-patient Novara study is hypothesis-generating. It does not establish ospemifene as a second-line OAB treatment or justify delaying guideline-supported OAB therapies.[6]
Proposed mechanism: estrogen-receptor activity in lower urinary tract tissues may affect bladder symptoms, but these small studies do not establish the mechanism or clinical equivalence to vaginal estrogen.[4][15]
Recurrent UTI prevention — not a primary indication
Unlike vaginal estrogen, ospemifene has not been specifically studied for rUTI prevention. The 2023 JAMA review notes that none of the FDA-approved GSM therapies (including ospemifene) are approved for reducing rUTI frequency.[2]
PEONY observational signal (breast cancer survivors, 6 months of ospemifene) — rUTIs decreased by 80% and postcoital cystitis decreased by 90% as secondary outcomes.[16] Hypothesis-generating.
Sexual function
Schiavi 2018 showed significant improvement in total FSFI and decreased sexual distress in women with VVA and OAB/UUI.[5] The 12-month PEONY study confirmed sustained improvements in lubrication and pain domains; overall FSFI total did not reach significance — likely reflecting the multifactorial nature of sexual dysfunction in this population.[17]
Guideline positioning
-
AUA/SUFU/AUGS 2025 GSM guideline: ospemifene may be offered for vulvovaginal dryness and/or dyspareunia (conditional recommendation, Grade C); this does not establish an OAB indication.[29]
-
ACOG — ospemifene can be recommended as an alternative to vaginal estrogen for dyspareunia caused by GSM (Level A recommendation)[18]
-
AGS Beers Criteria 2023 — lists ospemifene as a GSM-dyspareunia alternative alongside vaginal estrogen, DHEA, and hyaluronic acid[19]
-
AAFP 2023 — FDA-approved non-estrogen therapy for vaginal atrophy and dyspareunia[20]
Adverse effects and safety
Pooled safety (6 Phase 2/3 trials; n = 1,242 ospemifene vs n = 958 placebo):[12][21]
| AE | Ospemifene 60 mg | Placebo |
|---|---|---|
| Hot flush | 8.5% | 3.3% |
| UTI | 6.5% | 4.8% |
| Vaginal discharge | 3.8% | 0.3% |
| Muscle spasms | 3.2% | 0.9% |
| Headache | 2.4% | 2.3% |
| Hyperhidrosis | 1.6% | 0.3% |
| Vaginal hemorrhage | 1.0% | 0.2% |
| Night sweats | 1.0% | 0.0% |
| Discontinuation for AEs | 7.6% | 3.8% |
| Serious AEs | 2.6% | 1.8% |
Hot flashes (~8.5%) are the most clinically meaningful AE — counsel patients with pre-existing vasomotor symptoms that ospemifene may worsen hot flashes.[2][21]
Endometrial safety
Constantine 2015 Phase 2/3 pooled analysis (n = 1,242 ospemifene / n = 924 placebo):[10]
- No endometrial cancer in any ospemifene trial
- Endometrial hyperplasia: <1% at 12 months
- Proliferative endometrium: 26.3 per 1,000 women (ospemifene) vs 0 (placebo)
- Uterine polyps: 19.6 vs 8.3 per 1,000 women
Mean-thickness summaries should not obscure individual thickening or bleeding that needs assessment.[14] Progestogen co-administration was not evaluated in trials; FDA label does not mandate it. Long-term (>1 y) endometrial data are limited — counsel patients to report any postmenopausal bleeding.[10][12]
VTE risk — real-world signal favorable
| Source | n | VTE signal |
|---|---|---|
| Clinical trials (up to 15 mo) | Pooled | DVT 2.26 / 1,000 woman-y (2 cases) vs 3.15 / 1,000 (1 case) placebo — trials not powered for VTE[12] |
| Nordstrom 2020 MarketScan 2013–2017 | 8,188 ospemifene | 3.7 per 1,000 person-years VTE |
| Other SERMs | 11,777 | 11.5 per 1,000 person-years |
| Untreated VVA | 220,242 | 11.3 per 1,000 person-years |
Lower observed VTE rates in a claims cohort do not establish a protective effect or comparative safety because treatment selection and confounding may differ. The FDA contraindication for active or prior DVT/PE/stroke/MI remains.[22]
Perioperative
Per FDA label, discontinue ≥4–6 weeks before high-VTE-risk surgery or during prolonged immobilization.[12]
Bone and lipid effects
Bone
- Phase 3 data show significantly greater decreases in 7 of 9 bone biomarkers vs placebo at 12 weeks, comparable to raloxifene[7][8]
- Maffei 2022 observational 12-month study (n = 128) — stable BMD at total femur and lumbar spine on ospemifene; control group showed significant decline at all sites; bone alkaline phosphatase decreased[23]
- AYSEX real-world 12-month study (n = 100) — no significant change in DXA or bone-resorption markers[24]
- Not FDA-approved for osteoporosis — no fracture-outcome data; biomarker-level evidence only[7]
Lipids
Archer 2017 post-hoc analysis (n = 2,166):[11]
- HDL ↑ 4.4% at 3 mo, 5.1% at 6 mo (vs 0.2% / 1.5% placebo; p < 0.001)
- LDL decrease (p < 0.05)
- Triglycerides neutral (unlike oral estrogens)
Use in breast cancer survivors — regulatory divergence
| Source | Position |
|---|---|
| FDA label | Advises against use with known/suspected or a history of breast cancer; estrogen-dependent neoplasia is contraindicated[12] |
| EMA (Europe) | European labeling permits consideration for VVA only after all breast-cancer treatment, including adjuvant therapy, is completed; this is not proof of recurrence safety[28] |
| NCCN Survivorship 2026 | "Currently ospemifene is contraindicated in survivors with a history of estrogen-dependent cancers"[25] |
| ACOG 2021 clinical consensus | FDA warning is "controversial"; post-approval data have not demonstrated increased recurrence; recommend clinician-patient shared decision-making[18] |
Supporting clinical data
- Preclinical — antagonist activity in breast tissue; anti-proliferative effects[18][26]
- PEONY 6-month (n = 64 breast cancer survivors) — significant improvement in VVA symptoms and treatment satisfaction; decreased rUTIs and cystitis; no safety signals[16]
- PEONY 12-month (n = 385 overall; 145 ospemifene incl. breast cancer survivors) — sustained efficacy; ospemifene users had ~3× higher odds of clinically relevant satisfaction improvement vs local estrogen (OR 2.85; 95% CI 1.33–6.11)[17]
The US label advises against use in women with known/suspected or prior breast cancer. European labeling differs after completion of cancer treatment, but small uncontrolled studies and preclinical breast antagonism do not establish recurrence safety. Any discussion requires oncology involvement.[16][18][27]
Long-term efficacy and adherence
AYSEX 12-month real-world (n = 100)[24]
- Significant improvement in all VHI domains sustained at 12 months
- Only 1 patient remained with vaginal atrophy at 12 months (vs 100% at baseline)
- Significant improvement in sexual function and QoL
- No significant change in endometrial thickness, mammography, or bone health
PEONY 12-month (n = 385; 145 ospemifene / 240 local estrogen)[17]
- 75.9% ospemifene completion at 12 months (vs 78.7% local estrogen) — comparable adherence
- Treatment satisfaction 7.02 at 3 mo → 8.32 at 12 mo (p < 0.001)
- Favorable OR vs local estrogen for satisfaction improvement
Practical prescribing
| Parameter | Recommendation |
|---|---|
| Ideal candidate | Postmenopausal woman with moderate-to-severe dyspareunia or dryness who prefers oral therapy over vaginal application[12] |
| Dose | 60 mg PO daily with food (absorption is food-dependent)[12] |
| Onset | Significant improvement by 4–6 wk; full effect by 12 wk[2] |
| Duration | Indefinite; per FDA label, shortest duration consistent with treatment goals[12] |
| Progestogen | Not mandated; one simple hyperplasia without atypia and no cancer in trials through 52 weeks; evaluate abnormal bleeding[12] |
| Monitoring | Evaluate postmenopausal bleeding; no routine endometrial surveillance needed unless symptomatic[12] |
| Avoid in | Active / history of DVT-PE-stroke-MI; estrogen-dependent neoplasia; known/suspected or prior breast cancer; severe hepatic impairment; concurrent fluconazole or rifampin; pregnancy[12] |
| Perioperative | Discontinue 4–6 wk before high-VTE-risk surgery[12] |
| Counsel about | Hot flashes ~8.5%; vaginal discharge ~4%; take with food[21] |
| Breast cancer survivors | US label advises against use; European restrictions differ after completion of all cancer treatment; oncology discussion[18] |
| Cost | Brand-name only; ~$200–300/month uninsured |
Comparative summary — ospemifene vs vaginal estrogen vs vaginal DHEA
| Feature | Ospemifene (oral SERM) | Vaginal estrogen | Vaginal DHEA (prasterone) |
|---|---|---|---|
| Route | Oral | Vaginal (cream, insert, ring) | Vaginal insert |
| Dosing frequency | Daily with food | 2×/wk or 90-day ring | Daily at bedtime |
| FDA indications | Dyspareunia + vaginal dryness | GSM symptoms | Dyspareunia (US) |
| OAB improvement | Exploratory small observational studies; not established therapy[4][5][6][15] | Yes | Not studied |
| UTI prevention | Not formally studied (observational signal) | Strong evidence (RR 0.42) | Not studied |
| All-FSFI-domain sexual function | Lubrication + pain; desire/arousal inconsistent | Primarily pain / lubrication | All 6 domains including desire / arousal |
| Systemic exposure | Systemic SERM | Low with local low-dose formulations | Low, but estrogen/androgen metabolites can increase |
| Hot flashes | May worsen (~8.5%) | No effect | No effect |
| Bone effects | Favorable biomarkers (not FDA-approved) | None demonstrated | None demonstrated |
| Lipid effects | ↑HDL, ↓LDL, neutral TG | None | None |
| VTE considerations | Active/prior DVT/PE contraindication and boxed warning | Local low-dose observational evidence is reassuring | Rare-event comparative safety not established |
| Endometrial safety | Thickening and one simple hyperplasia without atypia; no cancer in 52-week trials | No hyperplasia (1 y data) | No hyperplasia (52 wk) |
| Breast cancer survivors | US label advises against use | Local low-dose therapy may be discussed after nonhormonal options | Label warning; limited evidence; oncology discussion when estrogen is not an option |
| Progestogen needed | No | No (low dose) | No |
| Generic | No | Yes (most) | No |
Evidence Summary
| Indication | Evidence level | Key source |
|---|---|---|
| Dyspareunia + vaginal dryness | Level 1 (Phase III + meta) | Di Donato 2019[13]; FDA label[12] |
| Endometrial safety (up to 52 wk) | Level 1 | Constantine 2015[10]; Simon 2023 NMA[14] |
| OAB / UUI improvement | Level 2 (prospective) | Schiavi 2017[4] / 2018[5]; Novara 2020[6]; Russo 2023[15] |
| Bone biomarkers | Level 2–3 | de Villiers 2019[7]; Maffei 2022[23] |
| Lipid effects | Level 2 | Archer 2017[11] |
| VTE in real-world use | Level 3 (PASS) | Nordstrom 2020[22] |
| Long-term efficacy / adherence (12 mo) | Level 3 | AYSEX[24]; PEONY[17] |
| Breast cancer survivors | Level 3 | PEONY[16][17]; ACOG consensus[18] |
Clinical Positioning
- Ospemifene 60 mg daily with food is the only oral, non-estrogen FDA-approved GSM therapy. Take-with-food matters — absorption nearly doubles with a fatty meal.[12]
- Avoid with fluconazole (2.7× AUC) and rifampin (58% AUC loss). The fluconazole interaction collides with common VVC management in the same patient population.[2][12]
- Ospemifene is not an established OAB/UUI treatment. Small uncontrolled bladder-symptom studies do not justify using it as a standard step before botulinum toxin or neuromodulation.[6]
- Not an rUTI-prevention agent. Vaginal estrogen retains the AUA-endorsed indication (RR 0.42). The PEONY observational signal is hypothesis-generating only.[16]
- Hot flashes are the dominant tolerance issue (~8.5%) and drive most discontinuations — counsel preemptively, particularly in women with pre-existing vasomotor symptoms.[2][21]
- Endometrial safety through 52 weeks is reassuring — no cancer, <1% hyperplasia; some patients developed thickening ≥5 mm. Long-term (>1 y) endometrial data remain limited; evaluate any postmenopausal bleeding.[10][14]
- Observational VTE comparisons do not establish protection or comparative safety. The active/prior DVT-PE-stroke-MI contraindications remain.[22]
- Discontinue 4–6 weeks before high-VTE-risk surgery or during prolonged immobilization per label.[12]
- Breast-cancer recommendations differ by jurisdiction. The US label advises against use with known/suspected or prior breast cancer; European labeling permits consideration only after all treatment is complete. PEONY cannot establish long-term recurrence safety.[18][17]
- Bone and lipid effects are favorable but off-label. Do not select ospemifene to treat dyslipidemia or osteoporosis on the basis of surrogate biomarkers.[7][11]
- Counsel about 4–6-week onset and 12-week full effect — realistic expectations improve adherence.[2]
See Also
References
1. US Food and Drug Administration. FDA Orange Book. Accessed 2026.
2. Crandall CJ, Mehta JM, Manson JE. "Management of menopausal symptoms: a review." JAMA. 2023;329(5):405–420. doi:10.1001/jama.2022.24140
3. Di Carlo C, Cagnacci A, Murina F, et al. "Ospemifene and vulvovaginal atrophy: an update of the clinical profile for post-menopausal women." Expert Opin Pharmacother. 2024;25(11):1541–1554. doi:10.1080/14656566.2024.2391009
4. Schiavi MC, Zullo MA, Faiano P, et al. "Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms." Gynecol Endocrinol. 2017;33(12):942–945. doi:10.1080/09513590.2017.1323859
5. Schiavi MC, Sciuga V, Giannini A, et al. "Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?" Gynecol Endocrinol. 2018;34(8):666–669. doi:10.1080/09513590.2018.1441398
6. Novara L, Sgro LG, Mancarella M, et al. "Potential effectiveness of ospemifene on detrusor overactivity in patients with vaginal atrophy." Maturitas. 2020;138:58–61. doi:10.1016/j.maturitas.2020.05.001
7. de Villiers TJ, Altomare C, Particco M, Gambacciani M. "Effects of ospemifene on bone in postmenopausal women." Climacteric. 2019;22(5):442–447. doi:10.1080/13697137.2019.1631789
8. Constantine GD, Kagan R, Miller PD. "Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women." Menopause. 2016;23(6):638–644. doi:10.1097/GME.0000000000000619
9. Franzoi MA, Agostinetto E, Perachino M, et al. "Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer." Lancet Oncol. 2021;22(7):e303–e313. doi:10.1016/S1470-2045(20)30666-5
10. Constantine GD, Goldstein SR, Archer DF. "Endometrial safety of ospemifene: results of the Phase 2/3 clinical development program." Menopause. 2015;22(1):36–43. doi:10.1097/GME.0000000000000275
11. Archer DF, Altomare C, Jiang W, Cort S. "Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data." Menopause. 2017;24(10):1167–1174. doi:10.1097/GME.0000000000000900
12. OSPHENA (ospemifene) prescribing information. DailyMed, accessed September 11, 2026.
13. Di Donato V, Schiavi MC, Iacobelli V, et al. "Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part I: evaluation of efficacy." Maturitas. 2019;121:86–92. doi:10.1016/j.maturitas.2018.11.016
14. Simon JA, Ferenczy A, Black D, et al. "Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis." Menopause. 2023;30(8):855–866. doi:10.1097/GME.0000000000002211
15. Russo E, Misasi G, Montt-Guevara MM, Giannini A, Simoncini T. "Effects of ospemifene on overactive bladder in postmenopausal women with vulvovaginal atrophy." Climacteric. 2023;26(3):284–288. doi:10.1080/13697137.2023.2184251
16. Villa P, Cassani C, Nappi RE, et al. "Quality of life and satisfaction with ospemifene for treating vulvovaginal atrophy in breast cancer survivors: six-month results from the PatiEnt SatisfactiON studY (PEONY)." Clin Breast Cancer. 2025. doi:10.1016/j.clbc.2025.08.001
17. Meriggiola MC, Villa P, Cagnacci A, et al. "Treatment of vulvovaginal atrophy is associated with high levels of satisfaction and improves symptom severity and patient-reported outcomes: 12-month results of the PatiEnt SatisfactiON studY (PEONY)." Menopause. 2026. doi:10.1097/GME.0000000000002737
18. American College of Obstetricians and Gynecologists. "Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus." Obstet Gynecol. 2021;138(6):950–960. doi:10.1097/AOG.0000000000004601
19. Steinman MA. "Alternative treatments to selected medications in the 2023 American Geriatrics Society Beers Criteria." J Am Geriatr Soc. 2025;73(9):2657–2677. doi:10.1111/jgs.19500
20. Chang JG, Lewis MN, Wertz MC. "Managing menopausal symptoms: common questions and answers." Am Fam Physician. 2023;108(1):28–39.
21. Simon JA, Altomare C, Cort S, Jiang W, Pinkerton JV. "Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials." J Womens Health. 2018;27(1):14–23. doi:10.1089/jwh.2017.6385
22. Nordstrom BL, Cai B, De Gregorio F, et al. "Incidence of venous thromboembolism among postmenopausal women prescribed ospemifene, selective estrogen receptor modulators for noncancer indications, or untreated vulvar and vaginal atrophy." Menopause. 2020;27(8):864–871. doi:10.1097/GME.0000000000001552
23. Maffei S, Guiducci L. "Effect of ospemifene on densitometric and plasma bone metabolism biomarkers in postmenopausal women reporting vulvar and vaginal atrophy (VVA)." J Clin Med. 2022;11(21):6316. doi:10.3390/jcm11216316
24. Pingarrón Santofímia C, Lafuente González P, Guitiérrez Vélez MDC, et al. "Long-term use of ospemifene in clinical practice for vulvo-vaginal atrophy: end results at 12 months of follow-up." Gynecol Endocrinol. 2022;38(7):577–582. doi:10.1080/09513590.2022.2083103
25. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: survivorship. Updated 2026-04-08.
26. Comini ACM, Carvalho BM, Moreira MJB, et al. "Safety and serum estradiol levels in hormonal treatments for vulvovaginal atrophy in breast cancer survivors: a systematic review and meta-analysis." Clin Breast Cancer. 2023;23(8):835–846. doi:10.1016/j.clbc.2023.08.003
27. Pinkerton JV, Vaughan MH, Kaunitz AM. "Hormonal medications for genitourinary syndrome of menopause." Clin Obstet Gynecol. 2024;67(1):68–78. doi:10.1097/GRF.0000000000000835
28. European Medicines Agency. Senshio product information. Breast-cancer treatment restrictions; regional policy is not a clinical recurrence-safety finding.
29. AUA/SUFU/AUGS. Genitourinary Syndrome of Menopause guideline. 2025; Statement 10.